Anzeige
Mehr »
Login
Mittwoch, 22.01.2025 Börsentäglich über 12.000 News von 682 internationalen Medien
STRONG BUY! Kurs eskaliert - A Star is Born!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: 940602 | ISIN: NL0000009538 | Ticker-Symbol: PHI1
Tradegate
21.01.25
21:50 Uhr
25,560 Euro
+0,410
+1,63 %
1-Jahres-Chart
KONINKLIJKE PHILIPS NV Chart 1 Jahr
5-Tage-Chart
KONINKLIJKE PHILIPS NV 5-Tage-Chart
RealtimeGeldBriefZeit
25,50025,53021.01.
25,52025,54021.01.
GlobeNewswire (Europe)
1.044 Leser
Artikel bewerten:
(2)

Royal Philips: Siloam Hospitals Group and Philips sign AI capability MoU to support Indonesia's healthcare transformation strategy

Finanznachrichten News

October 7, 2024

Jakarta, Indonesia and Amsterdam, the Netherlands -Royal Philips(NYSE: PHG, AEX: PHIA), a global leader in health technology, and Siloam Hospitals Group, Indonesia's leading private healthcare provider, have signed a Memorandum of Understanding (MoU) to advance AI capabilities and development in the healthcare sector in Indonesia.

The strategic collaboration, in partnership with the Universitas Pelita Harapan (UPH) Medical Sciences Group, will focus on capacity building, knowledge sharing, and implementing advanced AI solutions. Leveraging Philips' AI innovations, the collaboration will help transform clinical care and digital health, enhance healthcare delivery and make the healthcare infrastructure more sustainable. The goal is to deliver better care for more people in Indonesia.

This partnership aligns with the Indonesian government's healthcare strategy to improve healthcare accessibility, enhance clinical outcomes, and embrace digital transformation.

Key areas of focus in the partnership:

1. AI-driven clinical care: Philips intends to introduce its cutting-edge AI technologies into Siloam Hospitals, particularly in areas such as radiology, pathology, (interventional) cardiology and clinical operations. AI will enhance clinical decision-making and improve workflows, enabling healthcare professionals to diagnose and treat patients with greater precision and to enhance capacity of the system to be able support more patients.

2. Capacity building and local AI expertise: The MoU will focus on the development of local expertise in AI and digital health through collaboration with the UPH Medical Sciences Group. This initiative includes training programs to enable healthcare professionals, IT specialists and UPH students with the necessary skills to develop and apply AI in clinical settings.

3. Global knowledge sharing with Philips: As a global leader in informatics and AI for healthcare, Philips will share its expertise and global best practices with Siloam Hospitals and UPH. The collaboration includes aligning with Philips' informatics, AI research and global healthcare strategies to create scalable solutions tailored to the needs of Indonesia's healthcare system.


4. Digital health transformation: In support of Indonesia's digital health strategy, Siloam Hospitals will integrate AI into its healthcare management systems, including telemedicine, electronic medical records, and remote patient monitoring. The use of AI will improve patient outcomes, optimize hospital operations, increase capacity and provide patients with personalized, data-driven care, even in remote areas.

5. Supporting the Indonesian government's healthcare goals: The intended partnership aligns with the Indonesian government's strategy to enhance healthcare accessibility and quality.

6. Expertise sharing for driving ESG in healthcare: Philips will support Siloam Hospitals in advancing its ESG strategic priorities, including sustainability in the supply chain, environmental stewardship, fostering an equitable workplace, and expanding healthcare access and education.

Quotes from key leaders:

Caroline Riady, Deputy President Director of Siloam Hospitals Group: "This partnership with Philips, Siloam Hospitals and Universitas Pelita Harapan is a significant milestone in our journey to bring advanced healthcare technologies to Indonesia. By investing in AI capability and sharing global expertise, we are helping to build a smarter, more efficient healthcare system that will benefit millions of Indonesians and support the national healthcare agenda."

Roy Jakobs, Chief Executive Officer of Royal Philips: "At Philips, we believe that informatics and AI will help transform healthcare by optimizing workflows, improving efficiency and increasing capacity - making healthcare more accessible and delivering better care for more people. We are excited to collaborate with Siloam Hospitals and Universitas Pelita Harapan to drive this transformation and fully support the Indonesian government's vision of improving healthcare through digital innovation."

Rosan Roeslani, Minister of Investment of the Republic of Indonesia: "The future of healthcare is digital, and AI will play a crucial role in revolutionizing how care is provided. The partnership between Philips and Siloam Hospitals, which allows Indonesia to build local capabilities while tapping into global advancements in AI technology, is an exemplary collaboration to ensure the future economic development and sustainability of Indonesia."

For further information, please contact:

Mark Groves
Philips External Relations
Tel.: +31 631 639 916
E-mail: mark.groves@philips.com

About Royal Philips

Royal Philips.

Attachment

  • Leaders from Philips, Siloam Hospitals Group and the Indonesian government (https://ml-eu.globenewswire.com/Resource/Download/f6809a68-7872-4062-b158-8fa230a33d98)

© 2024 GlobeNewswire (Europe)
Gewinner im Megamarkt
Biotechnologie ist eine der bedeutendsten Zukunftstechnologien unserer Zeit. Zahlreiche Biotechnologie- und Pharmakonzerne haben sich unter anderem dem Kampf gegen Tumorerkrankungen verschrieben. Der weltweite Markt für Krebsmedikamente verzeichnet ein stetiges Wachstum. Für das Jahr 2025 wird ein Umsatz von etwa 190,3 Milliarden Euro prognostiziert, mit einer erwarteten jährlichen Wachstumsrate von 6,42% bis 2029, was zu einem geschätzten Marktvolumen von 244,1 Milliarden Euro führen würde.

Wir haben 3 aussichtsreiche Biotechnologieaktien mit Schwerpunkt Erforschung und Entwicklung von Wirkstoffen gegen Tumorerkrankungen ausfindig gemacht, die in den kommenden Monaten und Jahren erhebliches Aufwärtspotenzial versprechen und Vervielfachungspotenzial besitzen.

Fordern Sie jetzt unseren neuen kostenlosen Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien durchstarten und zu Ihrem Börsenerfolg in 2025 beitragen könnten!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.